Background. Cyclosporine A has been implicated in the pathogenesis of myocardial interstitial fibrosis observed in heart transplant recipients. However, other confounding variables such as posttransplantation hypertension and rejection episodes may also be responsible for interstitial fibrosis development and associated abnormalities in ventricular diastolic function. Therefore, we examined whether cyclosporine A directly or indirectly affects fibrillar collagen metabolism by cardiac fibroblasts in vitro.
Methods and Results. Rat cardiac fibroblasts were isolated by collagenase digestion. Subconfluent cultures were then maintained (24 hours) in serum-containing or serum-free medium before addition of cyclosporine A (50-1,000 ng/mL). After an additional 24 hours, total procollagen synthesis, accumulation, and degradation were analyzed by measuring hydroxyproline content in the cell monolayer and in the ethanol-soluble and ethanol-precipitable fractions of the culture medium. mRNA levels for al(I) and oil(III) procollagen polypeptides were assessed 2, 6, 12, and 24 hours after cyclosporine A treatment using Northern blot analysis. The results were compared with control cultures maintained in the absence of cyclosporine A. There were no differences in procollagen gene expression, total procollagen synthesis, accumulation, or degradation in cardiac fibroblasts treated directly with cyclosporine A, in concentrations up to 1,000 ng/mL, compared with untreated cells. In additional experiments, we examined whether cyclosporine A might stimulate the production of collagen regulatory substances by cardiac myocytes in culture. However, addition of conditioned media from neonatal myocytes maintained in the presence and absence of cyclosporine A (1,000 ng/mL) also had no effect on collagen deposition by cardiac fibroblasts.
Conclusions. We conclude that cyclosporine A has no direct effect on collagen metabolism by cultured cardiac fibroblasts in vitro. In addition, we have excluded a paracrine effect of ventricular myocytes on collagen production in the presence of cyclosporine A. These results suggest that factors other than cyclosporine A are responsible for the interstitial fibrosis observed in cardiac allografts. ( DNA. Blots were washed in 2xSSC-0.5% SDS (25°C, 20 minutes) and 0.lxSSC-0.1% SDS (65°C, 30 minutes). Prehybridization and hybridization with an oligonucleotide probe were performed at 51°C in a solution containing 6xSSC, 1 xDenhard's solution, 0.1% SDS, 0.05% Na pyrophosphate, 20 ,ug/mL tRNA, and 100 ,g/mL denatured salmon sperm DNA. Blots were washed in 6xSSC-0.1% SDS (65°C, 30 minutes). All blots were exposed to Kodak XAR-5 film with intensifier screens at -80°C for varying time periods. Band intensity was quantified by laser densitometry (LKB Ultrascan XL enhanced laser densitometer interfaced to a personal computer running GELSCAN XL Ver. 1.2). The cDNA clones used were human collagen type I, al(I), clone Hf67720; human collagen type III, a,(III), clone Hf9342'; and human glyceraldehyde 3-phosphate dehydrogenase (GAPDH), clone pHcGAP.22 All cDNA probes were obtained from the American Tissue Type Collection, Bethesda, Md. The inserts were isolated and labeled by random primer extension with (a-32P)dCTP. To ensure equal loading conditions, blots were also hybridized with an oligonucleotide probe specific for the rat 18S rRNA (5'-ACGGTATCTGATCGTCTTC-GAACC-3.23 The probe was end-labeled with (y-32p)_ ATP using T4 kinase and hybridized as previously described. 24 Immunofluorescent Staining Cells grown on glass coverslips were washed with 10 mM Na phosphate, 150 mM NaCI (pH 7.2; PBS) and fixed in 2% (wt:vol) paraformaldehyde in PBS for 10 minutes at room temperature (RT), followed by acetone for 15 minutes at -20°C. Cells were incubated with 10% (vol:vol) normal goat serum (1 hour, RT) and washed briefly with PBS. Type I procollagen was identified using a mouse monoclonal antibody specific for the aminoterminal cleavage site of a,(I) procollagen polypeptide. 25 The hybridoma cell line was obtained from the University of Iowa Hybridoma Bank, and the antibody was purified from conditioned media by protein G-Sepharose 4B affinity chromatography. Fixed (30 minutes, RT) . Type I collagen in the cell monolayer was identified using a polyclonal rabbit anti-rat antibody (1:100 dilution) and FITC-conjugated goat anti-rabbit IgG (Cappel, Westchester, Pa.). The gross morphology and immunofluorescent staining intensity and cellular distribution were evaluated by epifluorescent microscopy.
Quantitative Analysis of Procollagen Synthesis and Degradation
Procollagen synthesis was analyzed by measuring the amount of protein-bound hydroxyproline in the cell monolayer and conditioned medium 24 hours after exposure to cyclosporine A. The cell monolayer was scraped in 67% (vol:vol) ethanol, and the precipitate was collected by centrifugation (30, 000g, 30 minutes) . The protein sediment was redissolved and hydrolyzed in 6 N HCl (110'C, 16 hours) and decolorized with activated charcoal (70 mg). Similarly, the conditioned medium was mixed with 2 vol of absolute ethanol, and the resulting protein precipitate was hydrolyzed as described above. To estimate the amount of collagen degraded both intracellularly and extracellularly, the ethanol supernate from the conditioned medium was dried, and the residue was acid hydrolyzed.
[3H]Hydroxyproline (180,000 dpm) was added to each hydrolysis tube to serve as an internal standard for the recovery of hydroxyproline. Hydrolysates were evaporated to dryness, and the residue was dissolved in 1 mL H20. After derivatization of imino acids with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-CI), samples were chromatographed by reverse-phase high-performance liquid chromatography as described by Campa et al. 26 Hydroxyproline content was determined from the peak area, and derivatization efficiency was assessed by the recovery of [3H]hydroxyproline in the collected hydroxyproline peak. Data Shapiro test, and homogeneity of variance was established with Levine's test. Two-way randomized, blocked ANOVA was used to compare the factors of cyclosporine A and serum on measurements of collagen accumulation in cell monolayers. One-way, blocked ANOVA followed by Dunnett's test was used for comparisons between multiple groups. Paired and unpaired t tests were used for comparisons between two groups. Data were analyzed using the PROPHET computer system (Division of Research Resources, National Institutes of Health).
Results

Fibrillar Collagen mRNA Levels
Medium concentrations of cyclosporine A up to 1,000 ng/mL had no major effect on the mRNA levels for a,(I) and al(III) procollagen polypeptides (relative to either GAPDH mRNA or 18S rRNA) in cardiac fibroblasts harvested 12 hours after exposure to the drug ( Figure  1 ). Similar results were obtained at 2, 6, and 24 hours after addition of cyclosporine A.
Intracellular and Extracellular Localization of Type I Collagen
Medium concentrations of cyclosporine A up to 1,000 ng/mL had no effect on the morphology of cultured rat cardiac fibroblasts, as observed by phase-contrast microscopy (Figures 2A and 2B) . Total protein and DNA content of the cell monolayers also were unaffected by cyclosporine A treatment, indicating that the drug had no proliferative or toxic effects on these cells (data not shown). Furthermore, cyclosporine A treatment had no apparent effect on the subcellular distribution of newly synthesized type I procollagen ( Figures 2C and 2D) . The monoclonal antibody to the proaminopeptide domain of a,(I) procollagen polypeptide produced a reticular staining pattern throughout the cytoplasm of both untreated and cyclosporine A-treated fibroblasts. These results indicated that the intracellular level of newly synthesized type I procollagen was unaffected by the drug. Western blot analysis of cell monolayer proteins with this proaminopeptide antibody supported the above findings (data not shown). In addition, extracellular deposition of type I collagen by cardiac fibroblasts was not affected by the presence of cyclosporine A (Figures 2E and 2F) . The antibody to type I collagen revealed comparable amounts of mature collagen fibrils occupying the extracellular matrix within the cell monolayer of cyclosporine A-treated and untreated fibroblasts.
Direct Effects of Cyclosporine A on Collagen Production
The direct effect of cyclosporine A on collagen production by cardiac fibroblasts maintained in serum-free medium (DMEM/F12/PC-1) was assessed by measuring hydroxyproline in the cell monolayer as well as in the conditioned medium in the presence and absence of varying concentrations of the drug. As seen in Figure  3A , increasing doses of cyclosporine A did not affect the amount of ethanol-precipitable, hydroxyprolinecontaining proteins present in the medium after 24 hours. The amount of ethanol-precipitable, hydroxyproline-containing proteins in the cell monolayer was also unaffected by cyclosporine A (Figure 3B) . Finally, the mean-+-SD. Normality was assessed using the Wilk- C&A (ng/ml) FIGURE 3. Bar graphs of collagen production by cyclosporine A (CsM)-treated cardiac fibroblasts. Rat cardiac fibroblasts were grown in 35-mm plastic dishes, maintained for 24 hours in serum-free medium, and then treated for an additional 24 hours in medium containing 0-1,000 nglmL CsA. In panel A, medium hydroxyproline in ethanol-precipitable (closed bars) and ethanol-soluble (open bars) peptides and free amino acids was assayed by NBD-Cl derivatization and high-performance liquid chromatography. As is evident from the figure, increasing concentrations of CA had no effect on medium procollagen accumulation or degradation. In panel B, the amounts of ethanol-precipitable, hydroxyproline-containing peptides in the cell monolayer of CMA-treated fibro- amount of ethanol-soluble, hydroxyproline-containing peptides and free amino acid (produced by the degradation of both newly synthesized and mature collagens) was similar in control and cyclosporine A-treated cells ( Figure 3A) . Identical experiments were performed in serum-containing medium (FGM) in the presence and absence of a single concentration of cyclosporine A (1,000 ng/mL). The amount of hydroxyproline-containing peptides in all three fractions 24 hours after addition of the drug was found to be similar in both cyclosporine A-treated and untreated cultures (data not shown).
Indirect Effect of Cyclosporine A on Collagen Production
The amount of collagen deposited in the extracellular matrix of cultured cardiac fibroblasts (maintained in either DMEM/F12/PC-1 or FGM) was assessed 24 hours after exposure to conditioned media from neonatal myocytes maintained in serum-free culture in the presence or absence of cyclosporine A (1,000 ng/mL). As seen in Figure 4 , monolayer hydroxyproline content of fibroblasts maintained in FGM plus myocyte-condi- tioned medium was significantly greater than that observed in cells cultured in DMEM/F12/PC-1 plus myocyte-conditioned medium (p=0.004 for factor "serum," two-way ANOVA). However, prior exposure of myocytes to cyclosporine A had no effect on the fibroblast monolayer hydroxyproline content in either the presence or absence of serum (p=0.616 for factor "cyclosporine A," two-way ANOVA). Effect of Cyclosporine A on Human Peripheral Blood Mononuclear Cells
The effectiveness of the cyclosporine A that was used for all of the above experiments was tested for its ability to inhibit the proliferation of peripheral blood mononuclear cells stimulated with PHA in vitro. As seen in Figure 5 , cyclosporine A (1,000 ng/mL) markedly inhibited the proliferative response of mononuclear cells to PHA as indicated by its inhibition of [3H]thymidine incorporation. Thus, the absence of cyclosporine A effects on fibroblast collagen synthesis and degradation was not due to a lack of potency of the drug. Discussion In this report, we provide experimental evidence that cyclosporine A has no direct effect on collagen production or accumulation by cardiac fibroblasts in vitro. The concentrations of cyclosporine A used for these cell culture experiments were similar to or higher than the recommended blood levels used to prevent cardiac allograft rejection. With these doses of cyclosporine A, we were unable to demonstrate any alterations in steady-state mRNA levels for fibrillar collagen genes. Collagen production and the rate of collagen degradation also were unaffected by cyclosporine A in either the Although we have excluded a direct effect of cyclosporine A on collagen production by cardiac fibroblasts in vitro, indirect effects of the drug may influence collagen accumulation in the cardiac extracellular matrix in vivo. Uncontrolled, sustained hypertension has been shown to produce disproportionate collagen accumulation and myocardial interstitial fibrosis in experimental animals,27 with subsequent development of left ventricular dysfunction and congestive heart failure.28 Cyclosporine A is known to induce hypertension in humans,2 possibly mediated by sympathetic neural activation.29 Thus, the increased hemodynamic load produced by cyclosporine A treatment probably is related to the increased deposition of fibrillar collagens in the transplanted heart. However, it remains to be determined whether aggressive blood pressure reduction in the heart transplant recipient will reduce fibrillar collagen deposition in cardiac allografts. Furthermore, frequent rejection episodes with the release of cellular and humoral mediators of the immune response also may participate in increased procollagen production and interstitial fibrosis. Several investigators have shown that mononuclear leukocytes can release soluble mediators capable of stimulating30'31 or inhibiting32 collagen production in vitro. In addition, co-culture of mononuclear leucocytes with noncardiac fibroblasts resulted in increased collagen production,33 suggesting that cellcell interactions also may regulate collagen production during rejection episodes. It remains to be determined if cyclosporine A influences these cell-cell interactions contributing to the fibrotic response. However, we have excluded an effect of the drug on the production of myocyte regulatory factors that might influence collagen production and accumulation in this model system.
Collagen biosynthesis and turnover are regulated at pretranslational, translational, and posttranslational levels.34 Recent studies from this laboratory indicate that both pretranslational and posttranslational mechanisms modulate interstitial collagen accumulation in the rat heart during normal growth and hypertrophy. 35, 36 Based on this short-term, in vitro drug study, however, we conclude that cyclosporine A has no effect on any of the steps in procollagen biosynthesis and processing.
